Core Points - Aspo Plc executed a share repurchase on November 4, 2025, buying back 2,500 shares at an average price of €6.5120 per share, totaling a cost of €16,280.00 [1] - Following this transaction, Aspo Plc now holds a total of 4,768 shares, including those repurchased on the same date [1] - The share buybacks are conducted in compliance with the European Parliament and Council Regulation No. 596/2014 (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052 [1]

TAMPA, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced that its Board of Directors has authorized a share repurchase program to buy up to $1.5 million of the Company’s outstanding common stock. The authorization represents approximately 15% of LM Funding’s currently outstanding shares following its recently announced private repurchase of shares and warrants on October 30, 2025. Following ...

Core Viewpoint - Aspo Plc has announced a share repurchase program aimed at supporting its share-based incentive plans, with a maximum of 130,000 shares to be repurchased, representing approximately 0.42% of total shares [1][2]. Group 1: Share Repurchase Details - The repurchase will utilize a maximum of 1,000,000 euros and will be conducted through public trading on Nasdaq Helsinki at market prices [1][2]. - The share buybacks are set to commence on 4 November 2025 and will conclude by 30 April 2026 at the latest [2]. - Aspo Plc currently has a total of 31,419,779 shares, of which 2,268 are held as treasury shares [3]. Group 2: Regulatory Compliance and Authorization - The share repurchases will be executed in compliance with the Market Abuse Regulation and the Commission Delegated Regulation [3]. - A third-party broker has been appointed to carry out the repurchases independently, ensuring no influence from Aspo Plc [3]. - The Board of Directors has the authority to acquire up to 500,000 treasury shares, with the authorization valid until the Annual General Meeting in 2026, or for a maximum of 18 months from the approval date [4].

Financial Data and Key Metrics Changes - Consolidated revenues for the third quarter were $210 million, down 9.7% compared to the prior year quarter [5] - Operating income decreased by $10.1 million to $22.7 million compared to the prior year quarter [5] - Consolidated adjusted EBITDA was $40.4 million, a decrease of $11.9 million from the third quarter of fiscal 2024 [5] - Net earnings for the quarter were $16.2 million, or $0.52 per share, impacted by a non-recurring gain on a property insurance settlement of $3 million [5][6] - Excluding the gain, net earnings were $13.2 million, or $0.42 per share, compared to $24.8 million, or $0.78 per share in the prior year [6] Business Line Data and Key Metrics Changes Theater Division - Total revenue for the theater division was $119.9 million, a decrease of approximately 16% compared to the prior year [6] - Comparable theater admission revenue decreased by 15.8%, and attendance decreased by 18.7% compared to the fiscal third quarter 2024 [7] - Adjusted EBITDA for the theater division was $22.1 million, a 33% decrease over the prior year quarter [10] Hotels and Resorts Division - Total revenues before cost reimbursements were $80.3 million, a 1.7% increase compared to the prior year [10] - RevPAR for comparable owned hotels decreased by 1.5%, with an average occupancy rate of 78.4% [10][11] - Adjusted EBITDA for hotels was essentially flat compared to the prior year quarter [14] Market Data and Key Metrics Changes - U.S. box office receipts decreased by 12% during the fiscal 2025 third quarter compared to the previous year, indicating a trailing performance relative to the industry [7] - Comparable competitive hotels experienced a RevPAR decrease of 6.7%, indicating that the company's hotels outperformed the competitive set by 5.2 percentage points [12] Company Strategy and Development Direction - The company plans to continue pursuing growth investments while returning capital to shareholders through dividends and share repurchases [17][32] - Capital expenditures for fiscal 2025 are expected to be between $75 to $85 million, with a significant decrease anticipated in 2026 [15][32] - The company is focused on optimizing pricing strategies to capture premium during peak periods while maintaining value-oriented options for price-sensitive customers [24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a mixed quarter with solid results in hotels but challenges in theaters due to a less concentrated film slate [4][18] - The company remains optimistic about the upcoming film slate and expects continued growth in admission per caps [25][49] - There is an increased level of economic uncertainty, but the company is prepared to react and adjust quickly if needed [30] Other Important Information - The company repurchased approximately 600,000 shares for $9.1 million during the third quarter, totaling over 1 million shares repurchased this year [16] - The board approved a 4 million share increase in the current repurchase authorization, bringing it to 4.7 million shares [32] - The company celebrated its 90th anniversary, emphasizing its entrepreneurial legacy [33] Q&A Session Summary Question: On the hotel side, what is the situation with rate growth in three hotels? - Management indicated that the lack of rate growth was due to market dynamics, with two hotels facing persistent supply issues and one experiencing recent demand softening [36][37] Question: Is the $50 million to $55 million CapEx primarily maintenance? - Management confirmed that while it includes some ROI investments, it is primarily maintenance and ROI capital [38] Question: How does the company view M&A opportunities? - The company is comfortable with its current leverage and has capacity for M&A if attractive opportunities arise [40][41] Question: Have there been changes in consumer behavior regarding concessions? - Management noted no significant changes in consumer buying patterns, with consistent basket sizes and increased merchandise sales [42][43] Question: How does the company view the M&A market in the current macro environment? - Management observed a sluggish transaction volume but noted a potential increase in activity as interest rates decrease [44][45] Question: What are the expectations for admission per cap growth? - Management expects growth to continue, driven by strategic pricing moves implemented in the third quarter [46][47] Question: What growth opportunities does the company see for theaters and hotels? - Management highlighted the strong film slate for 2026 and the benefits of recent investments in hotel renovations [49][51]

Financial Data and Key Metrics Changes - Adjusted earnings per share for the third quarter was $1.62, representing a 4% year-over-year increase [18] - Reported sales increased by 6%, while core sales grew by 1% compared to the prior year [12] - Consolidated adjusted EBITDA margins increased by 30 basis points to 23.2% compared to 22.9% in the prior year [17] Business Line Data and Key Metrics Changes - Pharma segment's core sales increased by 2%, with prescription core sales up 3% and injectables core sales up 18% [14][15] - Consumer healthcare core sales decreased by 11%, primarily due to lower sales of nasal decongestants [14] - Beauty segment reported flat core sales, with personal care core sales increasing by 13% while fragrance and skincare sales decreased by 5% [15] - Closures segment core sales decreased by 1%, with product sales up 2% but offset by lower tooling sales [16] Market Data and Key Metrics Changes - The pharma segment saw strong demand for proprietary drug delivery systems, particularly for central nervous system therapeutics and GLP-1 medications [3][14] - The beauty segment experienced revenue growth in Asia and Latin America, while sales in Europe remained flat [5] - Food and beverage markets within the closures segment saw solid growth, while personal care declined [16] Company Strategy and Development Direction - The company is focused on ongoing growth and innovation within the pharma segment, including the acquisition of Somaplast to enhance its presence in Brazil [4][5] - Investments in research and development are emphasized, with over 10% of the pharma workforce dedicated to R&D [9] - The company aims to return capital to shareholders through share repurchases and increased dividends, reflecting confidence in long-term growth prospects [11] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued strength in the pharma business, particularly in injectables, despite near-term headwinds in emergency medicine [20][21] - The company expects core sales growth in beauty for Q4 and positive product sales volumes for closures [22] - The outlook for 2026 indicates a potential decline in emergency medicine revenues, but overall growth in other pharma segments is expected to remain strong [24][55] Other Important Information - The company recorded a gain of approximately $27 million from the remeasurement of a previously held minority interest, impacting net income positively [12] - Atypical litigation costs of approximately $4 million were incurred, which management emphasized do not reflect the underlying operational performance [13] Q&A Session Summary Question: Can you clarify the growth expectations for 2026 in pharma? - Management reiterated that the 7% to 10% growth expectation is based on a stable, growing business with innovation, but did not provide specific guidance for 2026 [28][29] Question: What are the next steps to drive higher margins in the beauty segment? - Management indicated that volume growth, regional performance, and innovation are key to improving margins in the beauty segment [35][36] Question: How significant is the margin difference for Narcan in emergency medicine? - Management confirmed that emergency medicine products, including Narcan, have a significant margin differential compared to other products [42] Question: What is the expected impact of emergency medicine on overall growth? - Management expects emergency medicine to contribute about 5% of total sales in 2025, with a projected decline of approximately 35% in 2026 [21][49] Question: Should the depreciation and amortization expense be carried forward? - Management confirmed that the increased depreciation and amortization expense should be considered a new run rate moving forward [50]

Core Viewpoint - First Interstate BancSystem is under pressure from activist investor HoldCo Asset Management, which has made several demands regarding the bank's capital management and strategic direction, but the bank has not fully committed to these demands [1][5][10]. Company Strategy - First Interstate's management has stated that they are not focused on mergers and acquisitions, opting instead to use excess capital for share buybacks [2][3]. - The bank's President and CEO, Jim Reuter, emphasized the importance of executing their strategic plan and expressed confidence in the bank's future success [3][9]. - The bank is transitioning towards relationship banking and has exited non-core businesses, including indirect auto lending [9]. Financial Performance - For the third quarter, First Interstate reported a net income of $71.4 million, representing a 28.6% increase year-over-year, with earnings per share of $0.69, exceeding the consensus estimate of $0.62 [13]. - Average loans decreased to $16.4 billion, a 12% year-over-year decline, attributed to the run-off of non-core relationships and recent branch sales [14]. Capital Management - HoldCo has requested that First Interstate publicly declare a goal to reduce its Common Equity Tier 1 (CET1) ratio target to 10.3%, significantly lower than the current ratio of 13.9% [5]. - The bank's CFO indicated that they would align their CET1 ratio more closely with peers in the near term, but no specific commitments were made regarding HoldCo's demands [5][11]. Market Reaction - First Interstate's stock price fell by 0.73% on the day of the news, and it has seen a decline of approximately 3% year-to-date [15].

Financial Data and Key Metrics Changes - SkyWest reported net income of $116 million, or $2.81 per diluted share for Q3 2025, reflecting a strong demand for its services [4] - Total Q3 revenue was $1.1 billion, up 15% from $913 million in Q3 2024, and up from $1 billion in Q2 2025 [9] - Q3 pre-tax income was $157 million, with an effective tax rate of 26% [9][10] - Cash at the end of Q3 was $753 million, up from $727 million in the previous quarter but down from $836 million in Q3 2024 [10] - Free cash flow generated in the first three quarters of 2025 was nearly $400 million, including $144 million in Q3 [11] Business Line Data and Key Metrics Changes - Contract revenue for Q3 was $844 million, slightly up from $842 million in Q2 2025 and significantly up from $761 million in Q3 2024 [9] - Pro-rate and charter revenue was $167 million in Q3, up from $145 million in Q2 and $123 million in Q3 2024 [9] - Leasing and other revenue was $39 million in Q3, down from $48 million in Q2 but up from $29 million in Q3 2024 [9] Market Data and Key Metrics Changes - SkyWest achieved over 185 days of 100% controllable completion year-to-date through Q3 2025, with over 2,500 daily scheduled departures [4] - Q3 block hours were up 2% compared to Q2 2025, with a projected 4% decrease in Q4 due to seasonality [19] Company Strategy and Development Direction - The company aims to restore or bring new service to underserved communities, redeploy its existing fleet, and prepare for future aircraft deliveries [8] - SkyWest plans to acquire and finance 30 additional E175s by the end of 2028 and repay approximately $500 million in debt in 2025 [12] - The company is focused on enhancing its fleet flexibility and maintaining strong partnerships to meet market demands [8][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth opportunities in 2026, including increased service to underserved communities and strong demand for pro-rate products [15] - The company is committed to navigating challenges posed by the federal government shutdown while honoring service commitments [5][27] - Management anticipates low single-digit percentage growth in block hours for 2026, translating into mid to high single-digit percentage growth in EPS [13][20] Other Important Information - The Department of Transportation finalized SkyWest Charter's commuter authorization, which is expected to provide future opportunities [5] - The company has secured firm delivery positions for 44 more E175s from 2028 to 2032, enhancing fleet flexibility [6] Q&A Session Summary Question: Can you walk us through the fleet and mixed benefit as you bring on more E175s? - Management noted that they expect to transition additional CRJ-550s into service and have strong pro-rate demand, which will offset some of the Delta-owned CRJ-900s being returned [23][24] Question: What is the status of Essential Air Service funding? - Management indicated that funding is secured through November 18, and they are committed to serving communities despite uncertainties regarding future reimbursements [26][27] Question: Can you clarify the multi-year agreement with United regarding CRJ-200s? - Management confirmed that the extended CRJ-200s are all contract airplanes, enhancing their partnership with United [28][29] Question: What is the impact of the 10% tariff from Brazil? - Management acknowledged the tariff's impact on small community service but emphasized their commitment to evolving and executing their strategy [34][35] Question: What are the net fleet additions expected for 2026? - Management projected flat to small increases in capacity purchase flying for 2026, with 20 CRJ-550s and 11 E175s being added, offset by the return of Delta-owned aircraft [38]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - Cardinal Health Inc. reported strong first-quarter 2026 earnings with adjusted earnings of $2.55 per share, exceeding the consensus estimate of $2.18 [1] - Sales increased by 22% year over year to $64.01 billion, surpassing the consensus estimate of $59.19 billion [1] - Adjusted operating earnings rose by 37% to $857 million [1] Segment Performance - Revenue for the Pharmaceutical and Specialty Solutions segment grew by 23% to $59.2 billion, driven by brand and specialty pharmaceutical sales [2] - The Global Medical Products and Distribution segment saw a 2% increase in revenue to $3.2 billion, attributed to volume growth from existing customers [2] Strategic Initiatives - Cardinal Health initiated a $375 million accelerated share repurchase program in the first quarter of fiscal year 2026 [2] - The company raised its fiscal 2026 adjusted earnings per share outlook from $9.30-$9.50 to $9.65-$9.85, above the consensus of $9.43 [4] - The increase in earnings guidance reflects strong first-quarter performance and expected contributions from the Solaris Health acquisition [4] Financial Expectations - The company expects profit growth in the Pharmaceutical and Specialty Solutions segment to be between 16%-19%, up from the prior guidance of 11%-13% [4] - Adjusted free cash flow expectations were raised to $3.0 billion to $3.5 billion, from a previous range of $2.75 billion to $3.25 billion [5] Market Reaction - Following the earnings report, Cardinal Health's stock surged by 16.55%, trading at $191.68 [5]

Financial Data and Key Metrics Changes - Total revenues for the third quarter were $596 million, down from $615 million in the prior quarter, primarily due to fewer operating days for the floater fleet [29] - Adjusted EBITDA was $163 million compared to $201 million in the prior quarter, with the decrease attributed to fewer operating days and a non-recurring benefit recognized in the previous quarter [30] - Adjusted free cash flow for the quarter was $237 million, with cash flow from operations amounting to $198 million [30] Business Line Data and Key Metrics Changes - The jackup segment saw increased EBITDA year over year, driven by more operating days and higher average day rates [13] - The drillship fleet added approximately $1.4 billion of backlog year to date, representing nine years of total contract duration [16] - The total backlog now stands at $4.5 billion, significantly enhancing contract coverage for 2026 and beyond [17] Market Data and Key Metrics Changes - Global utilization for the jackup fleet remains around 90%, driven by national oil companies focused on energy security [12] - The offshore drilling market is expected to see a recovery in utilization rates, with seventh-generation drillships anticipated to exit 2026 with utilization levels around 90% [11] - Demand for offshore drilling services is developing, particularly in deepwater projects, with a robust pipeline of opportunities expected [10] Company Strategy and Development Direction - The company remains focused on operational excellence, commercial execution, and disciplined cost management to drive long-term value for shareholders [4] - A strategic focus on securing attractive contracts has resulted in all four drillships with near-term availability being contracted for work beginning next year [9] - The company is in advanced discussions for additional contracts, particularly for rigs scheduled to complete contracts in the second half of 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term outlook for the offshore drilling industry, citing a need for sustained investment in oil and gas [10] - The company anticipates meaningful growth in deepwater project sanctioning over the next few years as customers pursue exploration and development [11] - Management highlighted the importance of ongoing investment to offset natural field declines, with the IEA estimating a potential 8% annual decline in global oil production without continued investment [10] Other Important Information - The company repurchased $75 million of shares during the quarter, reflecting its commitment to returning capital to shareholders [5] - The sale of the 27-year-old jackup Valaris 247 for $108 million was noted as part of the company's disciplined approach to cost management [14] - The company expects to receive approximately $70 million in upfront payments from customers this year for contract-specific upgrades [33] Q&A Session Summary Question: Share repurchase strategy and cash utilization - Management confirmed a commitment to returning capital to shareholders and indicated that repurchases would be opportunistic based on market conditions [40][42] Question: Exploration activity and customer discussions - Management noted an increase in exploration discussions, driven by the necessity to meet future energy needs, which is seen as positive for the market [46] Question: Future asset sales and shareholder returns - Management emphasized that operational cash flow will drive capital returns, with asset sales being opportunistic to enhance financial flexibility [48][50] Question: Day rates and market outlook - Management believes day rates for high-spec ships have troughed in the high $300,000s to low $400,000 range, with expectations for recovery in utilization and day rates [58][59] Question: Rig contracts and market dynamics - Management expressed confidence in securing extensions for rigs in Angola and highlighted ongoing discussions for gap-fill work for idle rigs [60][61]